BR9808858A - Terapias antitumores compreendendo uma combinação de um extrato de cartilagem e um agente antineoplástico provendo uma alta eficácia e baixos efeitos colaterais tóxicos - Google Patents

Terapias antitumores compreendendo uma combinação de um extrato de cartilagem e um agente antineoplástico provendo uma alta eficácia e baixos efeitos colaterais tóxicos

Info

Publication number
BR9808858A
BR9808858A BR9808858A BR9808858A BR9808858A BR 9808858 A BR9808858 A BR 9808858A BR 9808858 A BR9808858 A BR 9808858A BR 9808858 A BR9808858 A BR 9808858A BR 9808858 A BR9808858 A BR 9808858A
Authority
BR
Brazil
Prior art keywords
cartilage extract
combination
side effects
toxic side
providing high
Prior art date
Application number
BR9808858A
Other languages
English (en)
Inventor
Eric Dupont
Original Assignee
Aeterna Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeterna Lab Inc filed Critical Aeterna Lab Inc
Publication of BR9808858A publication Critical patent/BR9808858A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Patente de Invenção: <B>"TERAPIAS ANTITUMORES COMPREENDENDO UMA COMBINAçãO DE UM EXTRATO DE CARTILAGEM E UM AGENTE ANTINEOPLáSTICO PROVENDO UMA ALTA EFICáCIA E BAIXOS EFEITOS COLATERAIS TóXICOS"<D>. A presente invenção descreve um novo uso para extrato de cartilagem, isto é um extrato de cartilagem de tubarão, em uma terapia antitumor combinada. O extrato de cartilagem é usado em combinação com um antineoplástico. A terapia combinada proporciona um eficácia antitumor mais alta sem nenhum aumento concomitante, ainda melhor com uma redução de efeitos colaterais tóxicos.
BR9808858A 1997-03-11 1998-03-11 Terapias antitumores compreendendo uma combinação de um extrato de cartilagem e um agente antineoplástico provendo uma alta eficácia e baixos efeitos colaterais tóxicos BR9808858A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2199694 1997-03-11
PCT/CA1998/000202 WO1998040088A1 (en) 1997-03-11 1998-03-11 Compositions for treating tumors containing shark cartilage extracts and anti-neoplastic agents

Publications (1)

Publication Number Publication Date
BR9808858A true BR9808858A (pt) 2000-08-01

Family

ID=4160148

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808858A BR9808858A (pt) 1997-03-11 1998-03-11 Terapias antitumores compreendendo uma combinação de um extrato de cartilagem e um agente antineoplástico provendo uma alta eficácia e baixos efeitos colaterais tóxicos

Country Status (19)

Country Link
US (2) US6383522B1 (pt)
EP (1) EP0967987B1 (pt)
JP (1) JP2001500899A (pt)
KR (1) KR100417612B1 (pt)
CN (2) CN1824317A (pt)
AT (1) ATE241993T1 (pt)
AU (1) AU745769B2 (pt)
BR (1) BR9808858A (pt)
CA (1) CA2281570C (pt)
DE (1) DE69815310T2 (pt)
DK (1) DK0967987T3 (pt)
ES (1) ES2200316T3 (pt)
HK (1) HK1026364A1 (pt)
IL (1) IL131701A (pt)
NO (1) NO322847B1 (pt)
NZ (1) NZ337376A (pt)
PT (1) PT967987E (pt)
RU (1) RU2195946C2 (pt)
WO (1) WO1998040088A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
CN100441176C (zh) * 2001-09-24 2008-12-10 杰西·L·S·奥 测定联合疗法中使用的苏拉明的化学敏感化剂量的方法和组合物
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
JPWO2004083257A1 (ja) * 2003-03-20 2006-06-22 ホソカワミクロン株式会社 軟骨魚類から単離されたプロテオグリカンおよびその製造方法
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
WO2006059236A2 (en) * 2004-11-16 2006-06-08 Aeterna Zentaris Inc. Method of using cartilage extract for increasing blood parameters
CN105012953B (zh) 2005-07-25 2018-06-22 阿普泰沃研发有限责任公司 用cd37-特异性和cd20-特异性结合分子减少b-细胞
US7951782B2 (en) 2005-09-29 2011-05-31 Maruha Nichiro Seafoods, Inc Composition effective to prevent or treat adult disease
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
EP2167130A2 (en) * 2007-07-06 2010-03-31 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
EP2365003A1 (en) * 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
EA201890613A1 (ru) 2015-09-21 2018-10-31 Аптево Рисёрч Энд Девелопмент Ллс Полипептиды, связывающие cd3
WO2017201200A1 (en) * 2016-05-19 2017-11-23 Orphagen Pharmaceuticals, Inc. Therapeutic compositions containing rar-alpha antagonists

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE28093E (en) 1962-02-28 1974-07-30 Wound-healing cartilage powder
US3478146A (en) 1965-02-26 1969-11-11 Leslie L Balassa Wound-healing cartilage powder extracting process
US3966908A (en) 1973-11-29 1976-06-29 Lescarden Ltd. Method of treating degenerative joint afflictions
US4042457A (en) 1975-11-10 1977-08-16 Rush-Presbyterian-St. Luke's Medical Center Preparation of tissue invasion inhibitor and method of treatment utilizing the inhibitor
US4822607A (en) 1976-10-29 1989-04-18 Lescarden Ltd. Anti-tumor agent and method
US4212857A (en) 1976-10-29 1980-07-15 Lescarden Ltd. Method for stimulating the production of immunoglobulin and total complement
US4243582A (en) 1979-04-26 1981-01-06 Monsanto Company Novel glycoproteins from bovine cartilage
US4350682A (en) 1979-05-11 1982-09-21 Lescarden Ltd. Cartilage extraction processes and products
US4356261A (en) 1980-04-22 1982-10-26 Rush-Presbyterian-St. Luke's Medical Center Anti-invasion factor containing cultures
US4456589A (en) 1982-07-08 1984-06-26 Genetic Laboratories, Inc. Preparation of animal tissues for surgical implantation in human recipients
US4473551A (en) 1982-08-23 1984-09-25 Faxon Pharmaceuticals, Inc. Anti-inflammatory composition
JPS5939828A (ja) 1982-08-28 1984-03-05 Ajinomoto Co Inc 抗腫瘍活性物質の製造方法
US4444752A (en) 1982-09-13 1984-04-24 Lescarden Ltd. Method for treating progressive systemic sclerosis
US4469676A (en) 1983-06-21 1984-09-04 Michel Hecmati Method for eliminating wrinkles occurring in the human skin
JPS60178820A (ja) 1984-02-22 1985-09-12 Ajinomoto Co Inc 抗腫瘍活性物質の製造方法
US4656137A (en) 1985-09-12 1987-04-07 Lescarden Inc Method of processing animal cartilage
US4749522A (en) 1985-10-31 1988-06-07 Angio-Medical Corporation Supercritical fluid extraction of animal derived materials
US4746729A (en) 1986-07-30 1988-05-24 Kuettner Klaus E Cartilage-derived leukocyte elastase-inhibitor
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5096892A (en) 1988-05-27 1992-03-17 The Children's Medical Center Corporation Arylsulfatase inhibition and potentiation of angiostatic steroids and heparin
US5075112A (en) 1990-02-12 1991-12-24 Cartilage Technologies Inc. Method of and dosage unit for inhibiting angiogenesis or vascularization in an animal using shark cartilage
EP0571597A4 (en) 1991-11-15 1994-06-01 Arthro Res & Dev Corp Method for treatment of acute and chronic painful arthropathic conditions in human and other mammals
WO1994012510A1 (en) 1992-11-30 1994-06-09 Lane I William Processing shark cartilage
DK0797988T3 (da) 1993-07-19 2009-05-11 Univ British Columbia Anti-angiogene præparater og fremgangsmåder til anvendelse deraf
US5618925A (en) 1994-04-28 1997-04-08 Les Laboratories Aeterna Inc. Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof
US6025334A (en) * 1994-04-28 2000-02-15 Les Laboratoires Aeterna Inc. Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof
US6028118A (en) 1996-08-08 2000-02-22 Les Laboratoires Aeterna Inc. Methods of using extracts of shark cartilage
US5583153A (en) 1994-10-06 1996-12-10 Regents Of The University Of California Use of taxol in the treatment of rheumatoid arthritis
JPH11502514A (ja) * 1995-02-03 1999-03-02 レ ラボラトワール エテルナ インコーポレイティド サメ軟骨の抽出物、その製造法および使用
US5843920A (en) 1996-09-16 1998-12-01 Biocell Technology, Llc Anionic saccharides for extraction of anti-angiogenic protein from cartilage
US6168807B1 (en) 1998-07-23 2001-01-02 Les Laboratoires Aeterna Inc. Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof

Also Published As

Publication number Publication date
US6855338B2 (en) 2005-02-15
AU745769B2 (en) 2002-03-28
CN1824317A (zh) 2006-08-30
NO322847B1 (no) 2006-12-11
WO1998040088A1 (en) 1998-09-17
CA2281570C (en) 2003-09-23
DE69815310T2 (de) 2004-04-22
HK1026364A1 (en) 2000-12-15
KR20000075929A (ko) 2000-12-26
DK0967987T3 (da) 2003-09-22
ATE241993T1 (de) 2003-06-15
IL131701A (en) 2005-03-20
EP0967987A1 (en) 2000-01-05
AU6605598A (en) 1998-09-29
CN1250375A (zh) 2000-04-12
US20020146462A1 (en) 2002-10-10
ES2200316T3 (es) 2004-03-01
PT967987E (pt) 2003-10-31
IL131701A0 (en) 2001-03-19
EP0967987B1 (en) 2003-06-04
NZ337376A (en) 2002-02-01
CN1245993C (zh) 2006-03-22
NO994274L (no) 1999-11-09
CA2281570A1 (en) 1998-09-17
RU2195946C2 (ru) 2003-01-10
KR100417612B1 (ko) 2004-02-05
NO994274D0 (no) 1999-09-02
DE69815310D1 (de) 2003-07-10
US6383522B1 (en) 2002-05-07
JP2001500899A (ja) 2001-01-23

Similar Documents

Publication Publication Date Title
BR9808858A (pt) Terapias antitumores compreendendo uma combinação de um extrato de cartilagem e um agente antineoplástico provendo uma alta eficácia e baixos efeitos colaterais tóxicos
SG148031A1 (en) Use of cci-779 as an antineoplastic agent
FI962154A (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
ATE308999T1 (de) Intrazellulare expression von carboxypeptidase g2 in enzyme-prodrug-therapie
AU1565300A (en) Anti-germinating method for tubers and bulbs using eugenol and/or isoeugenol
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
MXPA97002401A (es) Agente antiinflamatorio para uso externo.
DE69905170T2 (de) Thiazolopyrimidinderivate
MXPA02007899A (es) Citoquinas modificadas para utilizarse en terapia de cancer.
AU1074902A (en) Kahalalide f
BR0210101A (pt) Combinações antineoplásticas
EP1162956B8 (en) Compositions and methods for improving integrity of compromised body passageways and cavities
MX9700298A (es) Adenovirus que comprende un gen que codifica para una no sintasa.
MX9805939A (es) Formas solidas de administracion, de liberacion instantanea y procesos para su produccion.
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
MD980129A (en) Antiherpetic remedy
IL143279A0 (en) Novel therapeutic application of low molecular weight heparin
PT925064E (pt) 5-androsteno-3beta,17alfa-diol como um inibidor do crescimento tumoral
TR199802496T2 (xx) Konjestif kalp yetmezli�ini tedavi i�in form�lasyon.
DE69726602D1 (en) Hepatitis b inhibitoren
NO981320L (no) Oral anvendelse av (+)-O-demetyltramadol som smertemiddel
WO2002066513A3 (de) Humane zirkulierende lekti fragmente hf7072, hf7638 und hf14448 sowie ihre verwendung
GB9723824D0 (en) Cytostatic agents
ES2141923T3 (es) Uso hipocolesterolemico, antiaterosclerotico e hipotrigliceridemico de derivados aminoacetilmercapto.
MXPA03000959A (es) Asociaciones dalfopristina/quinupristina con cefpiroma.

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADES.

B25D Requested change of name of applicant approved

Owner name: AETERNA ZENTARIS INC. (CA)

Free format text: ALTERADO DE: LES LABORATOIRES AETERNA INC.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A E 11A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2012 DE 28/07/2009.